The Effects of Spironolactone on Inflammation in a Rodent Model of Pulmonary Arterial Hypertension

螺内酯对肺动脉高压啮齿动物模型炎症的影响

• 批准号: 9352015
• 负责人: Jason Matthew Elinoff
• 金额: --
• 依托单位: CLINICAL CENTER
• 依托单位国家: 美国
• 资助国家: 美国
• 起止时间: 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/9352015
• 关键词: Animal Care and Use Committees; Animal Model; Cardiac Catheterization Procedures; Cardiovascular Diseases; Catheterization; Cell Culture Techniques; Cessation of life; Development; Diagnosis; Disease; Echocardiography; Exposure to; Goals; Heart; Heart failure; Hypoxia; Inflammation; KDR gene; Mineralocorticoid Receptor; Modeling; Patient-Focused Outcomes; Patients; Pharmaceutical Preparations; Procedures; Progressive Disease; Protocols documentation; Pulmonary Hypertension; Pulmonary artery structure; Rattus; Reproducibility; Rodent; Rodent Model; SU 5416; Side; Spironolactone; Stress; Structure; Subcutaneous Injections; Technical Expertise; Time; Work; eplerenone; heart function; improved; inhibitor/antagonist; pressure; pulmonary arterial hypertension; pulmonary artery endothelial cell

Since the time of Animal Care and Use Committee approval of this protocol in December 2015, we have been developing the necessary technical skills in rodent echocardiography and cardiac catheterization. Part 1 of the study, determining the reproducibility of the SU-5416/hypoxia/normoxia model by our group, as well as the development of the necessary catheterization and echocardiography procedures, commenced in August 2016. The study is currently ongoing. Our plans are to continue on to Part 2, determining the effects of spironolactone versus eplerenone in this model by early 2017.

自动物护理和使用委员会于 2015 年 12 月批准该协议以来，我们一直在开发啮齿动物超声心动图和心导管插入术方面必要的技术技能。该研究的第 1 部分于 2016 年 8 月开始，确定我们小组 SU-5416/缺氧/常氧模型的可重复性，以及开发必要的导管插入术和超声心动图程序。该研究目前正在进行中。我们的计划是继续进行第 2 部分，在 2017 年初之前确定螺内酯与依普利酮在此模型中的效果。